Li Hong-Xia, Lu Zhao-Hui, Shen Keng, Cheng Wen-Jun, Malpica Anais, Zhang Jing, Wei Jian-Jun, Zhang Zhi-Hong, Liu Jinsong
Department of Pathology, The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, P. R. China ; Department of Pathology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Department of Pathology, The University of Texas MD Anderson Cancer Center Houston, TX, USA ; Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, P. R. China.
Int J Clin Exp Pathol. 2014 Feb 15;7(3):848-57. eCollection 2014.
Early serous carcinoma in fallopian tube or serous tubal intraepithelial carcinoma (STIC), an early lesion limited to the epithelium of the fallopian tube and firstly identified from specimen obtained by prophylactic salpingo-oophorectomy, has provided insight into pelvic high grade serous carcinoma (HGSC). Increasing evidence indicates that STIC is a likely precursor for HGSC and several studies have focused on this lesion and its clinical significance. This review addresses recent advances in recognizing STIC and its correlation with HGSC and ovarian carcinogenesis. It also describes evidence regarding the fallopian tube as a source of some HGSCs, the protocol for optimizing histological evaluation of the tubes, the spectrum of tubal lesions from benign to noninvasive carcinoma, changes in diagnostic criteria from purely morphologic characteristics to a combination of morphologic features and molecular biomarkers, and new studies about potential biomarkers. However, the direct evidence regarding STIC as the precursor of HGSC is still tantalizing due to other possibilities that may also explain the origin of pelvic HGSC. Further molecular genetic studies are required to address this important question.
早期输卵管浆液性癌或输卵管浆液性上皮内癌(STIC)是一种局限于输卵管上皮的早期病变,最初是从预防性输卵管卵巢切除术中获得的标本中发现的,它为盆腔高级别浆液性癌(HGSC)的研究提供了线索。越来越多的证据表明,STIC可能是HGSC的前体,一些研究也聚焦于这一病变及其临床意义。这篇综述阐述了在识别STIC及其与HGSC和卵巢癌发生相关性方面的最新进展。它还描述了有关输卵管作为某些HGSC来源的证据、优化输卵管组织学评估的方案、从良性到非侵袭性癌的输卵管病变谱、诊断标准从单纯形态学特征到形态学特征与分子生物标志物相结合的变化,以及关于潜在生物标志物的新研究。然而,由于其他可能也能解释盆腔HGSC起源的因素,关于STIC作为HGSC前体的直接证据仍然不够确凿。需要进一步的分子遗传学研究来解决这个重要问题。